Inmagene Biopharmaceuticals
Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based company specializing in the research and pre-clinical development of therapies for immunology-related conditions. Founded in 2019, it focuses on addressing unmet medical needs globally through a unique approach termed "Borderless Innovation." The company is developing a pipeline of drug candidates, including IMG-020, a protein drug designed to target IL-17A, utilizing advanced technologies that enhance potency and extend the drug's half-life. Inmagene aims to create a new generation of therapeutics characterized by improved pharmacokinetics, pharmacodynamics, and safety profiles, which may lead to better efficacy and dosing convenience. With additional offices in Hangzhou and Beijing, Inmagene is committed to leveraging innovative resources and processes to facilitate drug development across borders, thereby enhancing the potential for positive patient outcomes worldwide.
Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.